November 17, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer Read More
October 30, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Upcoming Poster Presentation at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) Read More
October 29, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis Read More
October 14, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Upcoming Late-Breaking Oral and Poster Presentations at the 2025 American College of Rheumatology (ACR) Convergence Read More
October 6, 2025 by Jason Wertheimer Sonoma Biotherapeutics Congratulates Fred Ramsdell, PhD, Co-Founder and Scientific Advisory Board Chair, on Receiving the 2025 Nobel Prize in Physiology or Medicine for his work in Immunotherapy and Breakthrough Understanding of the Role of Regulatory T cells (Tregs) Read More
August 21, 2025 by Jason Wertheimer Sonoma Biotherapeutics Appoints Lisa Taylor Ash, JD, as Chief Legal Officer Read More
June 5, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress Read More
May 13, 2025 by Jason Wertheimer Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer Read More
May 6, 2025 by Jason Wertheimer Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Read More
September 4, 2024 by Jason Wertheimer Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration Read More